Moles and Melanoma: Symptoms, Self-Examination and Prevention

What is Moles and Melanoma?

Moles (medically known as nevi) are spots that appear on the skin when specific pigment-producing cells called melanocytes accumulate, forming a small cluster together with the surrounding tissue. They typically appear pink, light brown, dark brown, or skin-colored.

Melanocytes are epithelial cells found throughout the body’s surface. They produce melanin, the pigment responsible for skin color. When we are exposed to sunlight, melanocytes increase melanin production, causing the skin to tan.

Moles are extremely common. Most people have between 10 and 40 moles, and new ones can occasionally appear, typically up to the age of 40. They can be flat or slightly raised, and are usually round or oval, no larger than the diameter of a pencil eraser (approximately 6 mm). Many moles start out as small, flat spots and gradually become raised and larger over time. As the years pass, they may flatten again, fade in color, and sometimes disappear altogether.

Does Accidentally Cutting or Scraping a Mole Make It Dangerous?

No. Any accidental trauma to a benign mole, such as a cut or abrasion, does not change its nature. It also does not increase the risk of malignant transformation. However, moles that begin to bleed spontaneously without an apparent cause should be evaluated by a dermatologist promptly.

Can a Mole Be Removed for Cosmetic Reasons?

While melanoma is the most serious concern associated with moles, they can also cause other practical problems, such as:

• Getting caught on clothing or jewelry if raised,
• Becoming irritated through friction in areas subject to rubbing,
• Causing self-consciousness or embarrassment due to their size or location.

In all these cases, a dermatologist can safely remove the mole without any risk of triggering cancerous transformation.

Can I Cover a Mole with a Tattoo?

Tattooing over a mole is not advisable. If a melanoma were to develop in that area, the tattoo ink could make it significantly more difficult to notice early warning signs, potentially delaying a critical diagnosis.

Dysplastic Moles

Approximately 10% of people have at least one unusual or atypical mole, which looks different from their other moles. Dermatologists refer to these as dysplastic nevi (or atypical nevi).

Medical evidence suggests that dysplastic moles carry a higher risk than ordinary moles of developing into melanoma, which is a serious form of skin cancer. For this reason, regular monitoring by a dermatologist or an experienced physician is essential, particularly if a mole:

• Looks unusual or different from your other moles,
• Has grown larger,
• Has changed in color, outline, or any other characteristic.

The table below summarizes the key differences between normal moles and dysplastic moles:

The ABCDE Rule: The Alphabet of Moles

The ABCDE rule is a simple, memorable tool for identifying potentially suspicious moles. Importantly, a mole displaying one or more of these features is not necessarily malignant; it simply warrants professional evaluation. The five warning signs are:

• A - Asymmetry: Imagine drawing a line through the center of the mole. In a normal mole, both halves would be roughly mirror images. If the two halves look different, this is a warning sign.
• B - Border: The borders of a benign mole are smooth and well-defined. Irregular, ragged, notched, or blurred borders are suspicious.
• C - Color: A uniform color (brown or tan) is reassuring. Multiple colors within the same mole, such as shades of black, brown, red, white, or blue, should raise concern. You should also be alert if a mole is noticeably darker than all your others.
• D - Diameter: Most melanomas are larger than 6 mm (about the size of a pencil eraser) when diagnosed, although early melanomas can be smaller. Any mole larger than this should be evaluated.
• E - Evolution: Any change in a mole’s size, shape, color, or surface texture, or the development of new symptoms such as itching, bleeding, or crusting, warrants prompt medical attention.

Melanoma

Melanoma is one of the most serious forms of skin cancer because, in advanced stages, it is capable of spreading to other parts of the body through metastasis. It can also affect the eye (uveal melanoma) or, more rarely, other parts of the body where melanocytes are found, such as under the fingernails (subungual melanoma).

Melanoma develops when melanocytes undergo a genetic mutation and begin to proliferate in an uncontrolled, disorganized manner. Melanoma cells can invade and destroy surrounding healthy tissue, forming a malignant mass on the skin surface.

Melanoma can originate from a pre-existing mole or develop on previously unblemished skin. A dermatologist can assess whether an unusual-looking mole needs to be monitored or removed for further examination.

When detected in its early stages, before it has grown deeply into the skin or spread to other organs, melanoma can often be cured with a simple surgical procedure. In advanced stages, however, cancer cells may have already spread through the bloodstream or lymphatic system, forming secondary tumors (metastases) in other parts of the body. Advanced melanoma is significantly more difficult to treat.

Researchers and clinicians believe that many melanoma cases can be prevented. They also agree that most cases can be successfully managed when detected early. Because of this, awareness, self-examination, and routine dermatological check-ups are essential tools in the fight against this disease.

The Black Sheep Sign

An additional self-assessment tool that patients can use is the “black sheep sign” (also called the ugly duckling sign). This refers to one mole that is noticeably darker or more different-looking than all the others on the body. More specifically, it stands out when compared to other moles in the same anatomical region.

Even in the absence of other worrying features, a “black sheep” mole should prompt a dermatological consultation.

Risk Factors for Melanoma

Anyone can develop melanoma, but the following factors increase the likelihood:

• Personal or family history of melanoma.
• Presence of dysplastic (atypical) moles.
• Immunodeficiency or other immune system disorders.
• High number of ordinary moles (more than 50).
• Significant exposure to ultraviolet (UV) radiation and a history of severe sunburns with blistering, particularly during childhood or adolescence, can increase risks.
• Freckling (a marker of sun sensitivity).
• Very fair skin (low phototype: skin that burns easily and rarely tans).

Important: The presence of dysplastic moles or other risk factors does not mean you will develop melanoma. The vast majority of people with these risk factors never do. Conversely, approximately 50% of melanoma patients have no dysplastic moles and may have no other established risk factors.

---

Diagnosis

Early diagnosis is the single most powerful tool for reducing melanoma mortality. The modern diagnostic pathway involves several stages. It begins with informed self-examination at home and extends to precision digital technologies used by the dermatologist.

Clinical Assessment and Self-Examination

The first step toward timely diagnosis is the systematic, monthly self-examination of your skin. The following features should prompt immediate medical evaluation:

Self-examination should be performed monthly in a well-lit room. Remember to inspect less visible areas, such as the scalp, spaces between the toes, soles of the feet, and the back. You can use a mirror or ask a family member for assistance.

Specialist Examinations and Mole Mapping

During a specialist visit, the dermatologist uses dermoscopy, also called epiluminescence microscopy. This non-invasive technique relies on polarized light and magnification to reveal skin structures that are invisible to the naked eye. As a result, it significantly improves the accuracy of mole assessment.

For patients with a high number of moles or with dysplastic nevi, digital videodermoscopy (mole mapping) is often recommended. This procedure involves storing high-resolution images, which are then compared over time. This comparison allows for the detection of even minimal morphological changes, enabling the identification of incipient melanomas at their earliest stages.

Biopsy and Histological Examination

When a lesion is deemed suspicious, the dermatologist proceeds with excisional biopsy, which involves the surgical removal of the entire lesion. The removed tissue is then analyzed under the microscope by a pathologist to:

• Confirm or exclude the diagnosis of melanoma.
• Determine the Breslow thickness, which is the depth of tumor invasion into the skin. This is a critical prognostic parameter that guides subsequent treatment decisions.
• Assess other histological features such as ulceration and mitotic rate.

Staging and Biomarkers

For melanomas that exceed certain depth thresholds, clinical protocols include the sentinel lymph node biopsy. This procedure determines whether cancer cells have begun to spread into the lymphatic system. This is a key step in accurately staging the disease and planning appropriate treatment.

In advanced cases, staging is completed with imaging studies like CT scan, PET scan, or MRI, as well as molecular testing. This testing helps identify specific genetic mutations, such as:

• BRAF V600 (present in approximately 40–50% of cutaneous melanomas),
• NRAS,
• c-KIT.

These genetic “signatures” are now indispensable for selecting the most effective personalized therapies for each patient.

---

Treatment

The therapeutic approach to melanoma has undergone a radical revolution over the past decade, evolving from purely surgical management to a precision medicine model that integrates surgery, immunotherapy, and molecularly targeted agents. The primary goal is complete elimination of the local tumor and, in more advanced cases, systemic disease control.

Surgery

Surgical excision remains the gold-standard treatment for localized melanoma. Based on the histological findings, particularly the Breslow thickness, the surgeon performs a wide local excision. This procedure involves removing an additional margin of healthy skin around the biopsy scar to minimize the risk of local recurrence.

If the sentinel lymph node biopsy is positive, the management of the involved lymph node region is carefully considered. Current guidelines increasingly favor systemic pharmacological therapies over extensive and debilitating lymph node dissection in many patients.

Immunotherapy and Targeted Therapies

For patients with advanced-stage melanoma or those at high risk of recurrence, innovative treatments have dramatically transformed prognosis:

• Immunotherapy (Immune Checkpoint Inhibitors): These drugs, including anti-PD-1 agents like pembrolizumab and nivolumab, as well as anti-CTLA-4 agents such as ipilimumab, “awaken” the patient’s own immune system. This allows the immune system to recognize and destroy cancer cells. They are used both for metastatic disease and as adjuvant therapy (following surgery) to reduce the risk of recurrence.

• Targeted Therapy (Molecularly Targeted Agents): For patients whose melanoma carries a BRAF V600 mutation, oral targeted drugs such as BRAF inhibitors (vemurafenib, dabrafenib) combined with MEK inhibitors (trametinib, cobimetinib) block the specific signaling pathways that drive melanoma cell growth. These combinations often produce rapid and significant responses.

Neoadjuvant Therapies

An increasingly validated frontier approach consists of administering immunotherapy before the definitive surgical procedure (neoadjuvant therapy). This strategy aims to:

• “Train” the immune system against the tumor while it is still present,
• Potentially shrink the tumor, simplifying surgical removal,
• Improve long-term treatment efficacy.

Clinical trials have demonstrated impressive pathological response rates with neoadjuvant immunotherapy in resectable melanoma, and this approach is becoming an established option in clinical practice.

Lifestyle and Post-Treatment Management

Patient care does not end with the completion of surgery or drug treatment. Lifestyle plays a fundamental role in secondary prevention:

• Adopt a rigorous sun protection protocol: avoid direct sun exposure during peak hours (10 a.m. – 4 p.m.), wear protective clothing, wide-brimmed hats, and UV-blocking sunglasses, and apply broad-spectrum sunscreen correctly and consistently.
• Follow-up monitoring must be constant and thorough, including semi-annual or annual dermatological visits and, where indicated, periodic imaging studies.
• Psychological support can be valuable in managing the anxiety related to the risk of recurrence and in helping patients navigate the emotional challenges of a cancer diagnosis and treatment.

---

Survival Rates

Cutaneous melanoma most commonly affects individuals between the ages of 45 and 50, although the average age at diagnosis is progressively decreasing. It is fortunately rare in children.

According to U.S. SEER data, the 5-year overall survival rate for melanoma is approximately 93.7% when all stages are combined, a figure that reflects the substantial proportion of cases diagnosed at an early, localized stage.

• Localized melanoma (confined to the skin): 5-year survival ~99%
• Regional spread (to nearby lymph nodes): 5-year survival ~68%
• Distant metastases: 5-year survival ~30% (significantly improved by modern immunotherapy and targeted therapy)

The incidence of melanoma has doubled over the past 10 years and continues to rise, though it is important to note that cutaneous melanoma accounts for only about 5% of all skin tumors. Far more common are squamous cell carcinoma and basal cell carcinoma (basalioma).

---

Prevention

The number of people diagnosed with melanoma increases every year. In the United States alone, incidence has more than doubled over the past two decades, and comparable trends are observed across Europe. Experts attribute much of this rise to increased sun exposure and the widespread use of tanning beds.

Ultraviolet (UV) radiation from sunlight, sun lamps, and tanning beds damages skin DNA and is the primary preventable cause of melanoma and other skin cancers. UV rays are of two types: UVA (penetrates deeply, causes aging and DNA damage) and UVB (causes sunburn). Both types contribute to melanoma risk.

Practical Prevention Strategies

• Seek shade during peak UV hours (10 a.m. – 4 p.m.). A simple rule: if your shadow is shorter than your height, UV intensity is high, so seek protection.
• Wear protective clothing: long-sleeved shirts, wide-brimmed hats (at least 3-inch brim), and UV-protective clothing when working or exercising outdoors.
• Use broad-spectrum sunscreen (protecting against both UVA and UVB) with an appropriate SPF:
  • SPF 2–11: minimal protection.
  • SPF 12–29: moderate protection.
  • SPF 30 or higher: high protection, recommended for most people. It should be applied generously and reapplied every 2 hours (and after swimming or sweating).
• Wear UV-blocking sunglasses: look for lenses that block at least 99% of UVA and UVB radiation, which should be clearly stated on the label.
• Avoid tanning beds and sun lamps entirely, as the International Agency for Research on Cancer (IARC) classifies tanning devices as Group 1 carcinogens (definitely cancer-causing in humans).
• Perform monthly skin self-examinations and schedule annual dermatological check-ups, more frequently if you have risk factors such as dysplastic moles or a family history of melanoma.

Special note for children: Protecting children from sunburn is especially important, as severe sunburns in childhood and adolescence significantly increase the lifetime risk of melanoma.

---

Frequently Asked Questions

When should I worry about a mole? How do I recognize a dangerous one?

The vast majority of moles are completely harmless. However, you should consult a dermatologist in all doubtful cases. In particular, watch for changes and characteristics captured by the ABCDE rule:

• A – Asymmetry: Many melanomas lack symmetry and have irregular, uneven shapes.
• B – Border: A melanoma typically has irregular, jagged, or poorly defined borders.
• C – Color: The simultaneous presence of multiple colors within a single mole is a warning sign, as is a mole that is noticeably darker than all your others.
• D – Diameter: An increase in the size of a mole should be taken seriously, especially if it exceeds 6 mm.
• E – Evolution: Any change in shape, size, color, or surface texture deserves evaluation, as does the development of new symptoms such as itching, burning, or bleeding.

Also watch for the “black sheep” (ugly duckling) sign: a mole that looks visibly different from all the surrounding moles on that part of your body.

Is it dangerous to accidentally cut or injure a mole?

No, contrary to popular belief, an accidental injury (cut, scrape, or abrasion) to a benign mole cannot cause it to become malignant. However, a mole that bleeds spontaneously without any apparent cause should be evaluated by a dermatologist without delay.

Is it dangerous to surgically remove a mole for cosmetic reasons?

No. Surgical removal of a benign mole by a qualified dermatologist or surgeon carries no risk of triggering cancerous transformation. The procedure is safe, quick, and routinely performed.

---

Sources and Bibliography

• National Cancer Institute. Moles Fact Sheet. https://www.cancer.gov/types/skin/moles-fact-sheet
• American Academy of Dermatology. When is a mole a problem? https://www.aad.org/public/diseases/a-z/when-is-a-mole-a-problem
• SEER Cancer Statistics. Melanoma of the Skin. https://seer.cancer.gov/statfacts/html/melan.html
• Garbe C, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2022. Eur J Cancer. 2022.
• Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208–250.
• World Health Organization – International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Radiation, Vol. 100D. IARC, 2012.
• American Cancer Society. Melanoma Skin Cancer. https://www.cancer.org/cancer/melanoma-skin-cancer.html
• British Association of Dermatologists. Melanoma guidelines. https://www.bad.org.uk